Heron Therapeutics, Inc. (NASDAQ:HRTX) CEO Craig A. Collard Acquires 150,000 Shares

Heron Therapeutics, Inc. (NASDAQ:HRTX) CEO Craig A. Collard acquired 150,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 16th. The stock was purchased at an average cost of $0.92 per share, with a total value of $138,000.00. Following the acquisition, the chief executive officer now owns 186,496 shares in the company, valued at approximately $171,576.32. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Heron Therapeutics Stock Up 15.5 %

Shares of NASDAQ HRTX traded up $0.14 during trading on Friday, reaching $1.06. The company had a trading volume of 6,397,622 shares, compared to its average volume of 2,266,309. Heron Therapeutics, Inc. has a 12-month low of $0.50 and a 12-month high of $3.41. The stock has a market cap of $158.85 million, a PE ratio of -1.05 and a beta of 1.12. The business’s 50-day moving average is $0.87 and its 200 day moving average is $1.27.

Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings data on Monday, August 14th. The biotechnology company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.12). Heron Therapeutics had a negative return on equity of 21,127.62% and a negative net margin of 97.45%. The company had revenue of $31.76 million during the quarter, compared to the consensus estimate of $31.75 million. On average, analysts anticipate that Heron Therapeutics, Inc. will post -1.09 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages have weighed in on HRTX. Needham & Company LLC lowered their price objective on Heron Therapeutics from $5.00 to $4.00 and set a “buy” rating for the company in a research report on Wednesday. StockNews.com upgraded Heron Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. Rubric Capital Management LP raised its stake in shares of Heron Therapeutics by 127.3% in the third quarter. Rubric Capital Management LP now owns 26,713,503 shares of the biotechnology company’s stock worth $27,515,000 after buying an additional 14,963,503 shares during the period. State Street Corp raised its stake in Heron Therapeutics by 26.4% during the 2nd quarter. State Street Corp now owns 16,328,796 shares of the biotechnology company’s stock valued at $45,557,000 after purchasing an additional 3,405,427 shares during the period. Vanguard Group Inc. raised its stake in Heron Therapeutics by 3.4% during the 1st quarter. Vanguard Group Inc. now owns 9,934,688 shares of the biotechnology company’s stock valued at $56,827,000 after purchasing an additional 325,643 shares during the period. BlackRock Inc. raised its stake in Heron Therapeutics by 5.3% during the 3rd quarter. BlackRock Inc. now owns 9,258,303 shares of the biotechnology company’s stock valued at $39,071,000 after purchasing an additional 462,403 shares during the period. Finally, JPMorgan Chase & Co. grew its holdings in Heron Therapeutics by 4.9% during the 1st quarter. JPMorgan Chase & Co. now owns 7,086,791 shares of the biotechnology company’s stock valued at $10,701,000 after buying an additional 332,792 shares in the last quarter. Institutional investors own 81.77% of the company’s stock.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.